X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
aged (5) 5
female (5) 5
humans (5) 5
middle aged (5) 5
oncology (5) 5
adult (4) 4
chemotherapy (4) 4
index medicus (4) 4
breast cancer (3) 3
cancer (3) 3
disease-free survival (3) 3
survival (3) 3
treatment outcome (3) 3
aged, 80 and over (2) 2
antineoplastic agents - administration & dosage (2) 2
antineoplastic agents - adverse effects (2) 2
breast neoplasms - drug therapy (2) 2
double-blind (2) 2
her2/neu (2) 2
infusions, intravenous (2) 2
male (2) 2
open-label (2) 2
ovarian cancer (2) 2
ovarian neoplasms - drug therapy (2) 2
paclitaxel (2) 2
patients (2) 2
platinum (2) 2
randomization (2) 2
subcutaneous (2) 2
survival rate (2) 2
trastuzumab (2) 2
young adult (2) 2
abridged index medicus (1) 1
adenocarcinoma (1) 1
adenocarcinoma - drug therapy (1) 1
adenocarcinoma - mortality (1) 1
adenocarcinoma - pathology (1) 1
adjuvant (1) 1
antibodies, monoclonal, humanized - administration & dosage (1) 1
antibodies, monoclonal, humanized - adverse effects (1) 1
antibodies, monoclonal, humanized - therapeutic use (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
antineoplastic agents, hormonal - adverse effects (1) 1
antineoplastic agents, hormonal - therapeutic use (1) 1
apoptosis (1) 1
brca1 protein (1) 1
brca1 protein - genetics (1) 1
brca2 protein - genetics (1) 1
breast neoplasms - epidemiology (1) 1
breast neoplasms - metabolism (1) 1
breast neoplasms - pathology (1) 1
ca-125 (1) 1
ca-125 antigen - blood (1) 1
cancer therapies (1) 1
capsules (1) 1
carcinoma (1) 1
carcinoma, ovarian epithelial (1) 1
care and treatment (1) 1
cell death (1) 1
cell lung-cancer (1) 1
cell survival (1) 1
chemistry (1) 1
chemotherapy, adjuvant (1) 1
clinical trials (1) 1
cohort studies (1) 1
compounds thereof (1) 1
confidence intervals (1) 1
crushing, pulverising, or disintegrating (1) 1
crushing, pulverising, or disintegrating in general (1) 1
cystadenocarcinoma, serous - drug therapy (1) 1
cystadenocarcinoma, serous - genetics (1) 1
diagnosis (1) 1
double-blind method (1) 1
doxorubicin (1) 1
drug eruptions - etiology (1) 1
early termination of clinical trials (1) 1
end-points (1) 1
enzyme inhibitors (1) 1
epacadostat (1) 1
esophageal cancer (1) 1
esophageal neoplasms - drug therapy (1) 1
esophageal neoplasms - mortality (1) 1
esophageal neoplasms - pathology (1) 1
esophagogastric junction - pathology (1) 1
esophagus (1) 1
exanthema - chemically induced (1) 1
expression (1) 1
fallopian tube neoplasms - blood (1) 1
fallopian tube neoplasms - chemistry (1) 1
fallopian tube neoplasms - drug therapy (1) 1
fatigue - chemically induced (1) 1
growth factors (1) 1
hannah (1) 1
hematology, oncology and palliative medicine (1) 1
herceptin (1) 1
ido1 enzyme inhibitor (1) 1
immunotherapy (1) 1
indoleamine 2,3-dioxygenase (1) 1
indoleamine-pyrrole 2,3,-dioxygenase - analysis (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Shitara, Kohei and Özgüroğlu, Mustafa and Bang, Yung-Jue and Di Bartolomeo, Maria and Mandalà, Mario and Ryu, Min-Hee and Fornaro, Lorenzo and Olesiński, Tomasz and Caglevic, Christian and Chung, Hyun C and Chung, Hyun Cheol and Muro, Kei and Goekkurt, Eray and Mansoor, Wasat and McDermott, Raymond S and Shacham-Shmueli, Einat and Chen, Xinqun and Chen, Jen-Shi and Mayo, Carlos and Kang, S Peter and Ohtsu, Atsushi and Fuchs, Charles S and Lerzo, Guillermo and O'Connor, Juan Manuel and Mendez, Guillermo Ariel and Lynam, James and Tebbutt, Niall and Wong, Mark and Strickland, Andrew and Karapetis, Chris and Goldstein, David and Vasey, Paul and Van Laethem, Jean-Luc and Van Cutsem, Eric and Berry, Scott and Vincent, Mark and Muller, Bettina and Rey, Felipe and Zambrano, Angela and Guerra, Joaquin and Krogh, Merete and Baeksgaard, Lene and Yilmaz, Mette and Elme, Anneli and Magi, Andrus and Auvinen, Paivi and Alanko, Tuomo and Moehler, Markus and Kunzmann, Volker and Seufferlein, Thomas and Thuss-Patience, Peter and Hoehler, Thomas and Haag, Georg and Al-Batran, Salah-Eddin and Castro, Hugo and Lopez, Karla and Aguilar Vasquez, Mynor and Sandoval, Mario and Lam, Ka On and Cuffe, Sinead and Kelly, Cathy and Geva, Ravit and Hubert, Ayala and Beny, Alex and Brenner, Baruch and Giuseppe, Aprile and Falcone, Alfredo and Maiello, Evaristo and Passalacqua, Rodolfo and Montesarchio, Vincenzo and Hara, Hiroki and Chin, Keisho and Nishina, Tomohiro and Komatsu, Yoshito and Machida, Nozumo and Hironaka, Shuichi and Satoh, Taroh and Tamura, Takao and Sugimoto, Naotaoshi and Cho, Haruhiko and Omuro, Yashushi and Kato, Ken and Goto, Masahiro and Hyodo, Ichinosuke and Yoshida, Kazuhiro and Baba, Hideo and Esaki, Taito and Furuse, Junji and Wan Mohammed, Wan Zamaniah and Hernandez Hernandez, Carlos and Casas Garcia, Juan and Dominguez Andrade, Adriana and Clarke, Katriona and Hjortland, Geir and Glenjen, Nils and Kubiatowski, Tomasz and Jacek, Jassem and Wojtukiewicz, Marek and Lazarev, Sergey and Lancukhay, Yuri and ... and KEYNOTE-061 Investigators and KEYNOTE-061 investigators
The Lancet, ISSN 0140-6736, 07/2018, Volume 392, Issue 10142, pp. 123 - 133
Journal Article
British Journal of Cancer, ISSN 0007-0920, 10/2018, Volume 119, Issue 9, pp. 1075 - 1085
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 09/2017, Volume 146, Issue 3, pp. 484 - 490
Indoleamine 2,3-dioxygenase-1 (IDO1) is a key regulator of immune tolerance in ovarian cancer. This study investigated efficacy and safety of the IDO1 enzyme... 
Epacadostat | IDO1 enzyme inhibitor | Tamoxifen | Ca-125 | Ovarian cancer | SURVIVAL | DIAGNOSIS | PROTEIN | PROGNOSIS | INDOLEAMINE 2,3-DIOXYGENASE | OBSTETRICS & GYNECOLOGY | ONCOLOGY | IMMUNOTHERAPY | EXPRESSION | T-CELLS | Recurrence | Neoplasms, Glandular and Epithelial - chemistry | Oximes - pharmacokinetics | Oximes - adverse effects | Peritoneal Neoplasms - blood | Humans | Middle Aged | Oximes - therapeutic use | Response Evaluation Criteria in Solid Tumors | Fatigue - chemically induced | Peritoneal Neoplasms - chemistry | Antineoplastic Agents, Hormonal - adverse effects | Early Termination of Clinical Trials | Fallopian Tube Neoplasms - blood | Neoplasms, Glandular and Epithelial - blood | Peritoneal Neoplasms - drug therapy | Fallopian Tube Neoplasms - chemistry | Exanthema - chemically induced | Antineoplastic Agents, Hormonal - therapeutic use | Adult | Female | Ovarian Neoplasms - drug therapy | Pruritus - chemically induced | Fallopian Tube Neoplasms - drug therapy | Drug Eruptions - etiology | Ovarian Neoplasms - chemistry | CA-125 Antigen - blood | Indoleamine-Pyrrole 2,3,-Dioxygenase - analysis | Ovarian Neoplasms - blood | Survival Rate | Sulfonamides - pharmacokinetics | Disease-Free Survival | Sulfonamides - therapeutic use | Tamoxifen - therapeutic use | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Sulfonamides - adverse effects | Aged | Tamoxifen - adverse effects | Indoleamine-Pyrrole 2,3,-Dioxygenase - antagonists & inhibitors | Care and treatment | Chemotherapy | Enzyme inhibitors | Cancer | Medical research | Medicine, Experimental
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.